Max Lataillade

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance
    Max Lataillade
    Yale University School of Medicine, New Haven, CT, USA
    Antivir Ther 12:563-70. 2007
  2. doi request reprint A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results
    Michael J Kozal
    Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut, USA
    HIV Clin Trials 13:119-30. 2012
  3. doi request reprint Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants
    Shaili Gupta
    Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA
    J Int Assoc Physicians AIDS Care (Chic) 8:87-92. 2009
  4. doi request reprint Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels
    Michael J Kozal
    Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA
    Antivir Ther 16:925-9. 2011
  5. ncbi request reprint The hunt for HIV-1 integrase inhibitors
    Max Lataillade
    Division of Infectious Diseases, Yale University School of Medicine, LLCI 100D, 300 Cedar Street, Suite 169, New Haven, Connecticut 06520, USA
    AIDS Patient Care STDS 20:489-501. 2006

Detail Information

Publications5

  1. ncbi request reprint Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance
    Max Lataillade
    Yale University School of Medicine, New Haven, CT, USA
    Antivir Ther 12:563-70. 2007
    ....
  2. doi request reprint A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results
    Michael J Kozal
    Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut, USA
    HIV Clin Trials 13:119-30. 2012
    ..The reference regimen consisted of ATV 300 mg/RTV 100 mg qd + tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg qd (ATV/r+TDF/FTC)...
  3. doi request reprint Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants
    Shaili Gupta
    Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA
    J Int Assoc Physicians AIDS Care (Chic) 8:87-92. 2009
    ..All patients tolerated this regimen over a course of 25 to 82 weeks, and had good virologic and immunologic outcome with a decrease in HIV RNA levels to <50 copies/mL and a mean CD4 count increase of 234 cells/mm(3)...
  4. doi request reprint Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels
    Michael J Kozal
    Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA
    Antivir Ther 16:925-9. 2011
    ..The objectives of this study were to determine the prevalence of low-level K65R variants within different HIV-1 subtypes and to assess the effects of antiretroviral exposure on K65R variant levels...
  5. ncbi request reprint The hunt for HIV-1 integrase inhibitors
    Max Lataillade
    Division of Infectious Diseases, Yale University School of Medicine, LLCI 100D, 300 Cedar Street, Suite 169, New Haven, Connecticut 06520, USA
    AIDS Patient Care STDS 20:489-501. 2006
    ..Furthermore, we review the different INIs under development, their mechanism of actions, site of IN inhibition, potency, resistance patterns, and discuss the early clinical trial results...